Several reports describe how some men are using appetite-suppressing injections—described as coming from China and marketed for bulking up—despite potential health risks. The articles focus on a drug referred to as “Reta,” which they describe as being in the same family as diabetes and weight-loss medicines such as Ozempic and Mounjaro. The reporting characterizes “Reta” as stronger and notes that it is designed to target three hunger-related hormones, whereas other drugs in the same class are described as targeting one or two.
The coverage frames the use of these injections as a form of self-directed experimentation aimed at increasing body fat or muscle mass and improving what is described as “sexual market value.” The articles emphasize that the products being used are not presented as standard, physician-prescribed treatments, and they highlight concerns that people may be exposing themselves to unsafe or unregulated supply and potential side effects. The reports do not agree on specific incidence rates of harm, but they consistently present the practice as risky and caution against unregulated use.
